How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
Crossref DOI link: https://doi.org/10.1007/s40487-021-00153-5
Published Online: 2021-05-31
Published Print: 2021-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Untch, Michael
Martin, Miguel
De Laurentiis, Michelino
Gligorov, Joseph
Funding for this research was provided by:
Pierre Fabre
Text and Data Mining valid from 2021-05-31
Version of Record valid from 2021-05-31
Article History
Received: 23 March 2021
Accepted: 30 April 2021
First Online: 31 May 2021